$4803 | SAVE $847 | Single User
$5653 | SAVE $997 | Multi User
$6928 | SAVE $1,222 | Corporate License
$8500 | SAVE $1,500 | Enterprise License

Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021
[Published by MarketsandMarkets]

Published by MarketsandMarkets: 15 Sep 2016 | 19998 | In Stock
Related Topics: Assays , Blood , Microbiology , Molecular Diagnostics

Introduction

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021.

The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in the neonate and adult population across the globe. In addition, rising geriatric population, growing number of surgical procedures, high incidence of hospital-acquired infections, and increasing number of product approvals are supporting the growth of this market. On the other hand, lack of standard protocols and awareness as well as shortage of skilled staff are the major challenges in this market.

In this report, the sepsis diagnostics market has been segmented on the basis of product (instruments, blood culture media, assay kits & reagents, and software), technology (microbiology, molecular diagnostics, immunoassays, and flow cytometry), usability (laboratory testing & point-of-care testing), method (conventional diagnostics and automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, and others) and region (North America, Europe, APAC, and RoW). On the basis of products, the blood culture media segment is estimated to account for the largest share of the sepsis diagnostics market in 2016. High use of blood culture testing as the standard diagnostic method for the diagnosis and identification of sepsis is driving the growth of this segment across the globe.

Geographically, North America (comprising the U.S. and Canada) is expected to command the largest share of the sepsis diagnostics market in 2016, followed by Europe. A number of factors such as the high prevalence of sepsis, increasing number of invasive procedures, growing adoption of high-end sepsis diagnostics devices, and rising government support are contributing to the growth of the North American sepsis diagnostics market. However, lack of standard protocol for sepsis diagnostics and high cost of diagnostic devices are limiting the growth of sepsis diagnostics market in the North America.

The sepsis diagnostics market consists of a large number of big, medium, and small-sized companies. As of 2015, the sepsis diagnostics market was dominated by bioMérieux SA (France), Becton, Dickinson and Company (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Cepheid Inc. (U.S.). New product launches and product approvals; partnerships, agreements, and collaborations; and acquisitions; were the major strategies adopted by most of the market players between 2013 and 2016 to achieve growth in the sepsis diagnostics market.

OBJECTIVES OF THE STUDY

 To define, describe, and forecast the global sepsis diagnostics market on the basis of technology, products, method, usability, pathogen, and region

 To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

 To strategically analyze the micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market

 To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

 To provide a five-year forecast for various segments of the sepsis diagnostics market, in terms of revenue, with respect to four main regions, namely, North America (the U.S. and Canada), Europe (Germany, France, the U.K., and Rest of Europe), Asia-Pacific (India, China, Japan, and the Rest of Asia-Pacific), and the Rest of the World

 To strategically profile the key players and comprehensively analyze their market shares and core competencies2

 To track and analyze competitive developments such as new product launches,; agreements and partnerships,; and mergers and acquisitions in the global sepsis diagnostics market

1. Micromarkets are defined as the further segments and subsegments of the global sepsis diagnostics market included in the report.

2. Core competencies of the companies are captured in terms of their key developments and key strategies adopted to maintain their market positions.

Target Audience:

 Sepsis diagnostic device manufacturing companies

 Clinical laboratories

 Hospitals and clinics

 Research institutes and clinical research organizations (CROs)

 Market research and consulting firms

 Sepsis diagnostic devices suppliers and distributors

 Blood culture media manufacturers

 Blood culture media distributors and suppliers

Scope of the Report

This research report categorizes the sepsis diagnostics market into the following segments:

Global Sepsis Diagnostics Market, by Technology

 Microbiology

 Molecular Diagnostics

 Immunoassays

 Flow Cytometry

Global Sepsis Diagnostics Market, by Product

 Blood Culture Media

 Instruments

 Assays & Reagents

 Software

Global Sepsis Diagnostics Market, by Method

 Conventional Diagnostics

 Automated Diagnostics

Global Sepsis Diagnostics Market, by Usability

 Laboratory Testing

 Point-of-care Testing

Global Sepsis Diagnostics Market, by Pathogen

 Bacterial Sepsis

 Gram-negative Bacterial Sepsis

 Gram-positive Bacterial Sepsis

 Fungal Sepsis

 Others

Global Sepsis Diagnostics Market, by Region

 North America

 U.S.

 Canada

 Europe

 Germany

 France

 U.K.

 Rest of Europe

 Asia-Pacific

 India

 China

 Japan

 Rest of Asia-Pacific

 Rest of the World

Table of Contents
for Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021 [Published by MarketsandMarkets]

  • TABLE OF CONTENTS

    1 INTRODUCTION 17

    1.1 OBJECTIVES OF THE STUDY 17

    1.2 MARKET DEFINITION 17

    1.3 MARKET SCOPE 17

    1.4 MARKETS COVERED 18

    1.4.1 YEARS CONSIDERED FOR THE STUDY 18

    1.5 CURRENCY 19

    1.6 LIMITATIONS 19

    1.7 STAKEHOLDERS 19

    2 RESEARCH METHODOLOGY 20

    2.1 RESEARCH DATA 20

    2.1.1 SECONDARY DATA 21

    2.1.1.1 Key data from secondary sources 22

    2.1.2 PRIMARY DATA 22

    2.1.2.1 Key data from primary sources 23

    2.1.2.2 Key industry insights 24

    2.1.3 MARKET SIZE ESTIMATION METHODOLOGY 24

    2.1.3.1 Bottom-up approach 25

    2.1.3.2 Top-down approach 25

    2.1.4 RESEARCH DESIGN 26

    2.1.5 MARKET DATA VALIDATION AND TRIANGULATION 27

    2.1.6 ASSUMPTIONS FOR THE STUDY 28

    3 EXECUTIVE SUMMARY 29

    3.1 INTRODUCTION 29

    3.2 CURRENT SCENARIO 29

    3.3 FUTURE OUTLOOK 30

    3.4 CONCLUSION 33

    4 PREMIUM INSIGHTS 34

    4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL SEPSIS DIAGNOSTICS 34

    4.2 GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 35

    4.3 SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2016 VS. 2021 36

    4.4 SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD AND REGION, 2016 37

    4.5 SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2016 VS 2021 38

    4.6 SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2016 VS 2021 38

    5 MARKET OVERVIEW 39

    5.1 INTRODUCTION 39

    5.2 MARKET DYNAMICS 39

    5.2.1 DRIVERS 40

    5.2.1.1 High prevalence of sepsis in the neonate and adult population 40

    5.2.1.2 Rising incidence of sepsis in geriatric population 41

    5.2.1.3 Increasing number of preterm births 42

    5.2.1.4 Growing incidence of hospital-acquired infections 42

    5.2.1.5 Increasing number of surgical procedures 42

    5.2.1.6 Growing pneumonia cases 43

    5.2.1.7 Influx of novel sepsis diagnostic products 43

    5.2.2 RESTRAINTS 44

    5.2.2.1 High cost of automated diagnostic devices 44

    5.2.2.2 Lack of established reimbursement for sepsis 44

    5.2.3 OPPORTUNITIES 45

    5.2.3.1 Increasing funding for sepsis-related research activities 45

    5.2.3.2 Development of rapid diagnostic techniques for early sepsis diagnosis 45

    5.2.3.3 Evolution of Procalcitonin test as a novel biomarker for sepsis diagnosis 46

    5.2.3.4 Rising initiatives to increase the awareness and drive the adoption of sepsis diagnostic tests 47

    5.2.3.5 Growing number of regulatory approvals for sepsis diagnostic products 47

    5.2.4 CHALLENGES 48

    5.2.4.1 Lack of standard protocols and awareness for sepsis diagnosis and treatment 48

    5.2.4.2 Shortage of skilled healthcare professionals 48

    6 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT 49

    6.1 INTRODUCTION 50

    6.2 INSTRUMENTS 51

    6.3 BLOOD CULTURE MEDIA 52

    6.4 ASSAY KITS & REAGENTS 54

    6.5 SOFTWARE 55

    7 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY 57

    7.1 INTRODUCTION 58

    7.2 MICROBIOLOGY 59

    7.3 MOLECULAR DIAGNOSTICS 60

    7.4 IMMUNOASSAYS 62

    7.5 FLOW CYTOMETRY 64

    8 SEPSIS DIAGNOSTICS MARKET, BY METHOD 66

    8.1 INTRODUCTION 67

    8.2 CONVENTIONAL DIAGNOSTICS 68

    8.3 AUTOMATED DIAGNOSTICS 70

    9 SEPSIS DIAGNOSTICS MARKET, BY USABILITY 72

    9.1 INTRODUCTION 73

    9.2 LABORATORY TESTING 74

    9.3 POINT-OF-CARE TESTING 76

    10 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN 78

    10.1 INTRODUCTION 79

    10.2 BACTERIAL SEPSIS 80

    10.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS 81

    10.2.2 GRAM-POSITIVE BACTERIAL SEPSIS 82

    10.3 FUNGAL SEPSIS 82

    10.4 OTHER PATHOGEN INFECTIONS 84

    11 SEPSIS DIAGNOSTICS MARKET, BY REGION 86

    11.1 INTRODUCTION 87

    11.2 NORTH AMERICA 88

    11.2.1 U.S. 91

    11.2.1.1 Growing prevalence of sepsis 91

    11.2.1.2 Increasing incidences of HAIs 92

    11.2.1.3 Increasing government support for sepsis research 92

    11.2.1.4 Growing product approvals 92

    11.2.1.5 Rising initiatives to drive the adoption of sepsis diagnostic tools 92

    11.2.1.6 Lack of standard protocol for sepsis diagnosis hinders market growth 93

    11.2.1.7 High cost of treatment 94

    11.2.2 CANADA 96

    11.2.2.1 Expanding patient population base 96

    11.2.2.2 Support for the development of novel sepsis diagnostic products 96

    11.2.2.3 Growing focus on sepsis management 96

    11.2.2.4 Low awareness related to sepsis management 97

    11.2.2.5 Dearth of training leading to inadequate patient assessment 97

    11.3 EUROPE 99

    11.3.1 GERMANY 102

    11.3.1.1 High incidence of sepsis 102

    11.3.1.2 Growing funding for sepsis research 102

    11.3.1.3 Initiatives by the German Sepsis Society 102

    11.3.1.4 High awareness related to the sepsis management 103

    11.3.1.5 Development of novel sepsis diagnostics products 103

    11.3.1.6 Poor implementation of guidelines related to the sepsis management 103

    11.3.2 U.K. 105

    11.3.2.1 Growing initiatives by government organizations 105

    11.3.2.2 Increasing awareness among medical staff and general practitioners 106

    11.3.2.3 Rising focus towards the development of new sepsis diagnostics devices 106

    11.3.2.4 Rising demand for diagnostic devices 106

    11.3.2.5 Dearth of paramedics 106

    11.3.3 FRANCE 108

    11.3.3.1 Growing number of symposiums and conferences 108

    11.3.3.2 High prevalence of sepsis 109

    11.3.3.3 Growth in research funding for sepsis diagnosis 109

    11.3.4 REST OF EUROPE (ROE) 111

    11.3.4.1 Hub for various sepsis related conferences 111

    11.3.4.2 Rapid growth in the aging population 111

    11.3.4.3 Initiatives to diagnose neonatal sepsis 112

    11.3.4.4 Rising focus on the development of advanced products 112

    11.4 ASIA-PACIFIC 115

    11.4.1 JAPAN 118

    11.4.1.1 Increasing incidence of healthcare-associated infections 118

    11.4.1.2 Growing aging population 118

    11.4.1.3 Increasing initiatives by market players 118

    11.4.1.4 Lack of proper reimbursement for sepsis 119

    11.4.2 CHINA 121

    11.4.2.1 Large number of ongoing clinical studies 121

    11.4.2.2 Developing healthcare infrastructure 121

    11.4.2.3 Limited implementation of Surviving Sepsis Campaign (SSC) 121

    11.4.3 INDIA 123

    11.4.3.1 High sepsis burden 123

    11.4.3.2 Rising antibiotic resistance 124

    11.4.3.3 Rising number of ICU patients 124

    11.4.3.4 Increasing number of surgical procedures 124

    11.4.3.5 Rising focus of local and global players 124

    11.4.3.6 Shortage of medical staff in India 124

    11.4.3.7 Lack of awareness leading to death due to sepsis 125

    11.4.4 REST OF ASIA-PACIFIC 127

    11.4.4.1 Large number of ongoing conferences 127

    11.4.4.2 Rising initiatives to increase awareness about sepsis 127

    11.4.4.3 Significant patient population base in Malaysia 128

    11.4.4.4 South Korea presents significant growth opportunities 128

    11.4.4.5 Lack of established sepsis management guidelines 128

    11.4.4.6 Lack of reimbursement for sepsis 128

    11.5 REST OF THE WORLD 131

    11.5.1.1 Increasing antibiotic resistance among patients 131

    11.5.1.2 Initiatives to improve healthcare in Middle East countries 131

    11.5.1.3 High prevalence of cancer and HIV in the region 131

    11.5.1.4 Key challenges to market growth in the region 132

    12 COMPETITIVE LANDSCAPE 135

    12.1 OVERVIEW 135

    12.2 MARKET SHARE ANALYSIS 135

    12.3 COMPETITIVE SITUATION AND TRENDS 136

    12.3.1 PRODUCT APPROVALS 136

    12.3.2 COLLABORATIONS, ACQUISITIONS, AND PARTNERSHIPS 137

    12.3.3 NEW PRODUCT LAUNCHES 138

    12.3.4 OTHER STRATEGIES 139

    13 COMPANY PROFILES 141

    (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

    13.1 INTRODUCTION 141

    13.2 BIOMÉRIEUX SA 142

    13.3 BECTON, DICKINSON AND COMPANY 145

    13.4 THERMO FISHER SCIENTIFIC INC. 148

    13.5 ABBOTT LABORATORIES, INC. 151

    13.6 ROCHE DIAGNOSTICS LIMITED (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD.) 153

    13.7 CEPHEID INC. 155

    13.8 T2 BIOSYSTEMS, INC. 157

    13.9 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 159

    13.10 NANOSPHERE, INC. (A LUMINEX COMPANY) 161

    13.11 BRUKER CORPORATION 163

    *Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

    14 APPENDIX 165

    14.1 DISCUSSION GUIDE 165

    14.2 OTHER DEVELOPMENTS 169

    14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 171

    14.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 173

    14.5 AVAILABLE CUSTOMIZATIONS 174

    14.6 RELATED REPORTS 175

List Of Tables
in Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021 [Published by MarketsandMarkets]

LIST OF TABLES


TABLE 1 SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2014-2021 (USD MILLION) 50

TABLE 2 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET SIZE, BY REGION,

2014-2021 (USD MILLION) 52

TABLE 3 BLOOD CULTURE MEDIA MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 53

TABLE 4 ASSAY KITS & REAGENTS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 55

TABLE 5 SOFTWARE MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 56

TABLE 6 SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 58

TABLE 7 MICROBIOLOGY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 60

TABLE 8 MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 62

TABLE 9 IMMUNOASSAYS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 63

TABLE 10 FLOW CYTOMETRY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65

TABLE 11 SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD, 2014-2021 (USD MILLION) 67

TABLE 12 CONVENTIONAL DIAGNOSTICS MARKET SIZE, BY REGION,

2014-2021 (USD MILLION) 69

TABLE 13 AUTOMATED DIAGNOSTIC MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 71

TABLE 14 SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY, 2014-2021 (USD MILLION) 73

TABLE 15 PARAMETERS TESTED IN SEPSIS DIAGNOSIS 75

TABLE 16 LABORATORY TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 76

TABLE 17 POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 77

TABLE 18 SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2014-2021 (USD MILLION) 79

TABLE 19 BACTERIAL SEPSIS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION) 80

TABLE 20 BACTERIAL SEPSIS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 81

TABLE 21 FUNGAL SEPSIS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION) 83

TABLE 22 OTHER PATHOGEN INFECTIONS MARKET SIZE, BY REGION,

2014-2021 (USD MILLION) 85

TABLE 23 SEPSIS DIAGNOSTICS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 87

TABLE 24 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY,

2014–2021 (USD MILLION) 88

TABLE 25 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 88

TABLE 26 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 90

TABLE 27 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 90

TABLE 28 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 90

TABLE 29 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 91

TABLE 30 U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 94

TABLE 31 U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 94

TABLE 32 U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 95

TABLE 33 U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 95

TABLE 34 U.S.: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 95

TABLE 35 CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 97

TABLE 36 CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 97

TABLE 37 CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 98

TABLE 38 CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 98

TABLE 39 CANADA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 98

TABLE 40 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY,

2014–2021 (USD MILLION) 100

TABLE 41 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 100

TABLE 42 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 100

TABLE 43 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 101

TABLE 44 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 101

TABLE 45 EUROPE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 101

TABLE 46 GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 103

TABLE 47 GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 104

TABLE 48 GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 104

TABLE 49 GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 104

TABLE 50 GERMANY: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 105

TABLE 51 U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 107

TABLE 52 U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 107

TABLE 53 U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 107

TABLE 54 U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 108

TABLE 55 U.K.: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 108

TABLE 56 FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 109

TABLE 57 FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 110

TABLE 58 FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 110

TABLE 59 FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 110

TABLE 60 FRANCE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 111

TABLE 61 ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 113

TABLE 62 ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 113

TABLE 63 ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 113

TABLE 64 ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 114

TABLE 65 ROE: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 114

TABLE 66 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY COUNTRY,

2014–2021 (USD MILLION) 115

TABLE 67 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 115

TABLE 68 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 117

TABLE 69 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 117

TABLE 70 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 117

TABLE 71 APAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 118

TABLE 72 JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 119

TABLE 73 JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 119

TABLE 74 JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 120

TABLE 75 JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 120

TABLE 76 JAPAN: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 120

TABLE 77 CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 122

TABLE 78 CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 122

TABLE 79 CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 122

TABLE 80 CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 123

TABLE 81 CHINA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 123

TABLE 82 INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 125

TABLE 83 INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 126

TABLE 84 INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 126

TABLE 85 INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 126

TABLE 86 INDIA: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 127

TABLE 87 ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 129

TABLE 88 ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 129

TABLE 89 ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 129

TABLE 90 ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 130

TABLE 91 ROAPAC: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 130

TABLE 92 ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,

2014–2021 (USD MILLION) 132

TABLE 93 ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY PRODUCT,

2014–2021 (USD MILLION) 133

TABLE 94 ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY PATHOGEN,

2014–2021 (USD MILLION) 133

TABLE 95 ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY METHOD,

2014–2021 (USD MILLION) 133

TABLE 96 ROW: SEPSIS DIAGNOSTICS MARKET SIZE, BY USABILITY,

2014–2021 (USD MILLION) 134

TABLE 97 TOP 5 PRODUCT APPROVALS, 2013–2016 136

TABLE 98 TOP 5 COLLABORATIONS, ACQUISITION, AND PARTNERSHIPS, 2013–2016 137

TABLE 99 TOP 4 NEW PRODUCT LAUNCHES, 2013–2016 138

TABLE 100 TOP 5 OTHER STRATEGIES, 2013–2016 139

List Of Figures, Charts and Diagrams
in Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021 [Published by MarketsandMarkets]

LIST OF FIGURES


FIGURE 1 SEPSIS DIAGNOSTICS MARKET SEGMENTATION 18

FIGURE 2 GLOBAL SEPSIS DIAGNOSTICS MARKET: RESEARCH METHODOLOGY STEPS 20

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 23

FIGURE 4 TOP-DOWN APPROACH 25

FIGURE 5 DATA TRIANGULATION METHODOLOGY 27

FIGURE 6 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2016 30

FIGURE 7 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016 (USD MILLION) 31

FIGURE 8 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2016 VS. 2021 31

FIGURE 9 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY USABILITY, 2016 VS. 2021 32

FIGURE 10 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2016 VS. 2021 32

FIGURE 11 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2016 (USD MILLION) 33

FIGURE 12 INCREASING PREVALENCE OF SEPSIS—PRIMARY DRIVER OF THE SEPSIS DIAGNOSTICS MARKET 34

FIGURE 13 BLOOD CULTURE MEDIA SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016 35

FIGURE 14 MICROBIOLOGY SEGMENT WILL CONTINUE TO DOMINATE THE SEPSIS DIAGNOSTICS MARKET IN 2021 36

FIGURE 15 CONVENTIONAL DIAGNOSTICS SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016 37

FIGURE 16 LABORATORY TESTING SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016 38

FIGURE 17 BACTERIAL SEPSIS SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS MARKET IN 2016 38

FIGURE 18 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40

FIGURE 19 CHANCES OF DEVELOPING SEPSIS INCREASE WITH AGE, 2014 41

FIGURE 20 PATIENT SURVIVAL RATE IN SEPSIS CASES 46

FIGURE 21 BLOOD CULTURE MEDIA SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD (2016- 2021) 50

FIGURE 22 NORTH AMERICA TO DOMINATE THE INSTRUMENTS MARKET IN 2016 51

FIGURE 23 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE BLOOD CULTURE MEDIA MARKET, 2016 53

FIGURE 24 NORTH AMERICA TO DOMINATE THE ASSAY KITS & REAGENTS MARKET IN 2016 54

FIGURE 25 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE SOFTWARE SEGMENT

(2016-2021) 56

FIGURE 26 MOLECULAR DIAGNOSTICS SEGMENT TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD (2016-2021) 58

FIGURE 27 NORTH AMERICA TO DOMINATE THE MICROBIOLOGY MARKET IN 2016 59

FIGURE 28 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE MOLECULAR DIAGNOSTICS MARKET IN 2016 61

FIGURE 29 NORTH AMERICA TO DOMINATE THE IMMUNOASSAYS MARKET IN 2016 63

FIGURE 30 NORTH AMERICA TO DOMINATE THE FLOW CYTOMETRY MARKET IN 2016 64

FIGURE 31 CONVENTIONAL DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE SEPSIS DIAGNOSTICS MARKET IN 2021 67

FIGURE 32 NORTH AMERICA TO DOMINATE THE CONVENTIONAL DIAGNOSTICS MARKET

IN 2016 69

FIGURE 33 ASIA-PACIFIC TO WITNESS HIGH GROWTH IN THE AUTOMATED DIAGNOSTICS SEGMENT DURING THE FORECAST PERIOD, 2016-2021 71

FIGURE 34 POCT SEGMENT TO WITNESS HIGHEST GROWTH DURING THE FORECAST PERIOD, 2016-2021 73

FIGURE 35 NORTH AMERICA TO DOMINATE THE LABORATORY TESTING MARKET IN 2016 75

FIGURE 36 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE POINT-OF-CARE TESTING SEGMENT (2016-2021) 77

FIGURE 37 BACTERIAL SEPSIS SEGMENT TO WITNESS HIGHEST GROWTH, 2016–2021 79

FIGURE 38 GRAM-NEGATIVE BACTERIA SEGMENT TO DOMINATE THE BACTERIAL SEPSIS MARKET IN 2016 80

FIGURE 39 ASIA-PACIFIC TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD, (2016-2021) 81

FIGURE 40 NORTH AMERICA TO DOMINATE THE FUNGAL SEPSIS MARKET IN 2016 83

FIGURE 41 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH IN THE OTHER PATHOGENS SEGMENT IN 2016 84

FIGURE 42 SEPSIS DIAGNOSTICS MARKET: GROWTH FORECAST, BY REGION (2016–2021) 87

FIGURE 43 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 89

FIGURE 44 EUROPE: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 99

FIGURE 45 APAC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT 116

FIGURE 46 GLOBAL SEPSIS DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015 135

FIGURE 47 BATTLE FOR MARKET SHARE: PRODUCT APPROVALS THE KEY STRATEGY 136

FIGURE 48 GEOGRAPHIC REVENUE MIX OF THE TOP PLAYERS 141

FIGURE 49 BIOMÉRIEUX SA: COMPANY SNAPSHOT 142

FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 145

FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 148

FIGURE 52 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT 151

FIGURE 53 ROCHE DIAGNOSTICS LIMITED: COMPANY SNAPSHOT 153

FIGURE 54 CEPHEID: COMPANY SNAPSHOT 155

FIGURE 55 T2 BIOSYSTEMS, INC.: COMPANY SNAPSHOT 157

FIGURE 56 DANAHER CORPORATION: COMPANY SNAPSHOT 159

FIGURE 57 LUMINEX CORPORATION: COMPANY SNAPSHOT 161

FIGURE 58 BRUKER CORPORATION: COMPANY SNAPSHOT 163

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

19998 | MD 4575

Number of Pages

176

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Sepsis Partnering Market Research Report Forecast 2017 to 2021
The Global Sepsis Partnering Market Research Report Forecast 2017-2021 is a valuable source of insig...
10 May 2017 by S&P Consulting USD $2,380 (normally
USD $2,800)
More Info
SAVE 15% today! Bacterial Sepsis Global Clinical Trials Review, H1, 2017
Bacterial Sepsis Global Clinical Trials Review, H1, 2017SummaryGlobalData's clinical trial report, “...
30 Apr 2017 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Global Sepsis Partnering 2010 to 2017
The Global Sepsis Partnering Terms and Agreements since 2010 report provides understanding and acces...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Sepsis Diagnostics Market: Size, Trend, Share, Opportunity Analysis & Forecast, 2014–2025
Sepsis is a bloodstream infection in which there is a massive immune response and may lead to organ ...
01 Mar 2017 by Progressive Markets USD $3,076 (normally
USD $3,619)
More Info
SAVE 15% today! Sepsis - Pipeline Review, H1 2017
Sepsis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare...
28 Feb 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Sepsis Partnering 2010 to 2017
The Global Sepsis Partnering Terms and Agreements since 2010 report provides understanding and acces...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Sepsis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Sepsis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Sepsis Global Clinical Trials Review, H2, 2016
Sepsis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Sepsis Glo...
31 Aug 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Sepsis Global Clinical Trials Review, H2, 2016
Sepsis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report, “Sepsis Glo...
31 Aug 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Sepsis Diagnostics Market by Technology (Molecular Diagnostics, Microbiology, Immunoassay), Product (Instrument, Blood Culture Media), Method (Conventional & Automated), Usability (Laboratory & POC), Pathogen (Bacterial & Fungal) - Global Forecast to 2021 [Published by MarketsandMarkets] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...